Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus André J. Scheen Review Article 14 January 2014 Pages: 295 - 304
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets Huixin YuNeeltje SteeghsAlwin D. R. Huitema Review Article 25 February 2014 Pages: 305 - 325
Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings Iftekhar Mahmood Review Article 11 February 2014 Pages: 327 - 346
Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients Ahmed Hamed SalemDenise KoenigDawn Carlson Original Research Article 04 December 2013 Pages: 347 - 359
Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients Kun WangDavid Z. D’ArgenioIghovwerha Ofotokun Original Research Article 06 December 2013 Pages: 361 - 371
Influence of Gestational Age and Body Weight on the Pharmacokinetics of Labetalol in Pregnancy James H. FischerGloria E. SartoKeith A. Rodvold Original Research Article 03 December 2013 Pages: 373 - 383
Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug Fabrice BalavoineMichel AziziCatherine Llorens-Cortes Original Research Article 13 December 2013 Pages: 385 - 395